1. Home
  2. KNSA vs KYMR Comparison

KNSA vs KYMR Comparison

Compare KNSA & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kiniksa Pharmaceuticals Ltd.

KNSA

Kiniksa Pharmaceuticals Ltd.

N/A

Current Price

$95.50

Market Cap

7.7B

Sector

Health Care

ML Signal

N/A

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

N/A

Current Price

$121.03

Market Cap

9.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KNSA
KYMR
Founded
2015
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
9.0B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
KNSA
KYMR
Price
$95.50
$121.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
24
Target Price
$111.57
★ $145.22
AVG Volume (30 Days)
869.4K
★ 912.7K
Earning Date
10-27-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 225.00
N/A
EPS
★ 1.14
N/A
Revenue
★ $677,564,000.00
$39,211,000.00
Revenue This Year
$54.80
$153.48
Revenue Next Year
$28.50
N/A
P/E Ratio
$83.44
★ N/A
Revenue Growth
★ 60.09
N/A
52 Week Low
$37.02
$63.69
52 Week High
$99.31
$142.92

Technical Indicators

Market Signals
Indicator
KNSA
KYMR
Relative Strength Index (RSI) 58.64 47.18
Support Level $72.76 $104.96
Resistance Level $98.90 $128.95
Average True Range (ATR) 4.32 7.47
MACD -0.24 -1.35
Stochastic Oscillator 68.28 14.51

Price Performance

Historical Comparison
KNSA
KYMR

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Share on Social Networks: